CT-3 is a synthetic cannabinoid
Overview


Science and Research
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial
Title | Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. | |
---|---|---|
Author(s) | Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. | |
Journal, Volume, Issue | JAMA 2003;290(13):1757-62 | |
Major outcome(s) | Significant reduction of pain | |
Indication | Pain | Abstract |
Medication | Other cannabinoids | CONTEXT: 1',1'dimethylheptyl-Delta8-tetrahydrocannabinol-11-oic acid (CT-3), a
All Conditions Benefited by Medical Marijuana |
Route(s) | Oral | |
Dose(s) | 4 x 10-mg - 8 x 10 mg | |
Duration (days) | 7 | |
Participants | 21 patients with chronic neuropathic pain | |
Design | Controlled study | |
Type of publication | Medical journal | |
Address of author(s) | Department of Anesthesiology, Pain Clinic, Hannover Medical School, Hannover, Germany. karst.matthias@mh-hannover.de | |
Full text | ![]() |